The rapid growth of cannabis-based medicines is becoming a significant disruptor of the global pharmaceutical industry, but the point of entry has been complicated by the historic scheduling of cannabis as a schedule 1 narcotic. However, pharmaceutical cannabis products such as Epidyolex, Sativex and Dronabinol have become serious alternatives to traditional pharmaceuticals and are beginning to shift how the pharma industry approaches cannabis.
The Pharmaceutical Cannabis Report examines:
- Prohibition Partners estimates that worldwide sales for pharmaceutical cannabinoid therapeutics will total almost US$800 million in 2020.
- Epidiolex® remains the leading pharmaceutical cannabis products. In the US, it enjoyed sales of over US$116.1 million in Q1 2020 and US$117.7 million in Q2 2020.
- Existing pharmaceutical cannabis products will achieve growth rates of 150% between 2020 and 2024 to reach total value sales just shy of US$2 billion.
The Pharmaceutical Cannabis Report is now available both in digital and print versions for purchase: https://prohibitionpartners.com/reports/the-pharmaceutical-cannabis-report/?utm_source=PP+Master+List&utm_campaign=d7dd6d561f-EMAIL_CAMPAIGN_UK_Disrupting_Food_COPY_01&utm_medium=email&utm_term=0_20e7a0ae35-d7dd6d561f-68951071&mc_cid=d7dd6d561f&mc_eid=e2114bb512